NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.
18/11/2010NanoViricides One2One Investor Presentation - 18th November 2010
Presentations & Company Media
No documents available.
Related Research & Media
23/06/2011Eugene Seymour interview (Audio/Video)
The Company is a pre-clinical biotech company focused on an evolving $100B world-wide market. We are developing drugs aimed at the destruction of viruses in the body. The Company has drug candidates against nine different viruses. These are currently being studied in animals. These viruses include Ebola, Marburg, adenovirus and herpes simplex virus of the external eye, HIV, rabies, dengue and all influenza viruses. All of the drugs consist of a nanomicelle (a polymer-based 20nm lipophilic structure) that is attached to a ligand (receptor molecule). All that is needed to target a new virus is to change the ligand.
CEO: Eugene Seymour, MD, MPH
Chairman and President : Anil R. Diwan, PhD
CSO: Randall Barton, PhD
CRO:Krishna Menon, VMD, PhD, MRCS
135 Wood Street
West Haven, CT 06516
No info available.